The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

Multiple myeloma (MM) is a tumor of plasmablasts/plasma cells (PCs) characterized by the expansion of malignant PCs with complex genetic aberrations in the bone marrow (BM). Recent reports, by us and others, have highlighted the polycomb group (PcG) proteins as potential targets for therapy in MM. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzrigat, Mohammad, Párraga, Alba Atienza, Majumder, Muntasir Mamun, Ma, Anqi, Jin, Jian, Österborg, Anders, Nahi, Hareth, Nilsson, Kenneth, Heckman, Caroline A., Öberg, Fredrik, Kalushkova, Antonia, Jernberg-Wiklund, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732762/
https://www.ncbi.nlm.nih.gov/pubmed/29262596
http://dx.doi.org/10.18632/oncotarget.21909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732762/
https://www.ncbi.nlm.nih.gov/pubmed/29262596
http://dx.doi.org/10.18632/oncotarget.21909

Ejemplares similares